- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04566900
Neurofeedback to Improve Working Memory in Mild Cognitive Impairment
September 21, 2023 updated by: Fiza Singh, University of California, San Diego
Enhancing Gamma Band Response in Mild Cognitive Impairment to Improve Working Memory
Mild cognitive impairment (MCI) has been identified as an early phase of Alzheimer's disease (AD), a neurodegenerative disorder expected to affect 13.9 million Americans by 2060.
AD causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality.
Treatment intervention at the MCI stage of the disease could potentially slow down the rate at which people may convert from MCI to AD. Increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in AD.
Furthermore, previous research has shown that neurofeedback (NFB) training targeting these regions can improve memory, making it a potential treatment for AD.
NFB is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor.
We are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with MCI.
Results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with MCI.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, clinical trial to test the efficacy of gamma-neurofeedback (G-NFB) compared to a placebo (P-NFB) in individuals with MCI.
112 consented participants will be randomized to receive G-NFB (n=56) or placebo-NFB (n=56) during 30-45 minute sessions twice per week for 12 weeks (24 total sessions).
Memory and other cognitive domains will be measured using paper and pencil and computerized tests every 4 weeks during the study and at 4 weeks post completion of study.
Study Type
Interventional
Enrollment (Estimated)
112
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fiza Singh, M.D.
- Email: fsingh@health.ucsd.edu
Study Contact Backup
- Name: Joshua Phillips, B.S.
- Phone Number: 858-267-2257
- Email: j7phillips@health.ucsd.edu
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- University of California at San Diego
-
Contact:
- Fiza Singh, MD
- Phone Number: 858-922-4365
- Email: fsingh@ucsd.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Meet criteria for mild cognitive impairment (MCI).
- Living independently.
- Literate in English.
- Competent to participate in the informed consent process and provide voluntary informed consent.
Exclusion Criteria:
- Frontal temporal dementia
- Active alcohol or substance use disorder within the past year.
- Brain cancer
- Stroke within the last 2 years
- Anti-epileptic medication
- Prior head injury involving loss of consciousness
- Seizure disorder
- Use of medications likely to affect cognitive function (cf. donepezil, memantine). We will not exclude for other medications but will examine their effects and include medications as covariates as appropriate (e.g., presence v. absence; anticholinergic load).
- The potential benefits of the study do not outweigh the potential risks of the study, as determined by the PI.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Treatment
Subjects will be given a choice of videos consisting of still images set to music.
Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range.
Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
|
Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor.
For instance, frontal brain activity may be shown as an airplane flying.
Once the activity is made accessible, the subject can modulate it in a pre-specified direction.
The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
|
Sham Comparator: Placebo
Video and music progression will be random and will not depend on brain activity.
Any progression will be by random chance alone.
|
Subjects in this arm will undergo all of the same testing as active treatment.
Music and video progression will not depend on brain activity.
Instead feedback will be random.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Working Memory accuracy
Time Frame: From baseline to 12 weeks of treatment
|
Change in the computerized test, N-back will be used to measure working memory.
|
From baseline to 12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Durability of Change in Working Memory accuracy
Time Frame: From baseline to 4weeks post end of study
|
Change in the computerized test, N-back will be used to measure working memory.
|
From baseline to 4weeks post end of study
|
Change in Gamma Band Response
Time Frame: From baseline to 12 weeks of treatment
|
Change in Gamma oscillations will be measured while the subject performs the n-back task.
|
From baseline to 12 weeks of treatment
|
Durability of Gamma Band Response
Time Frame: From baseline to 4weeks post end of study
|
Change in Gamma oscillations will be measured while the subject performs the n-back task.
|
From baseline to 4weeks post end of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-68. doi: 10.1146/annurev-psych-113011-143750. Epub 2012 Sep 27.
- Dohnel K, Sommer M, Ibach B, Rothmayr C, Meinhardt J, Hajak G. Neural correlates of emotional working memory in patients with mild cognitive impairment. Neuropsychologia. 2008 Jan 15;46(1):37-48. doi: 10.1016/j.neuropsychologia.2007.08.012. Epub 2007 Aug 23.
- Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA. Changes in brain functional connectivity in Alzheimer-type and multi-infarct dementia. Brain. 1992 Oct;115 ( Pt 5):1543-61. doi: 10.1093/brain/115.5.1543.
- Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron. 2006 Oct 5;52(1):155-68. doi: 10.1016/j.neuron.2006.09.020.
- Stam CJ, van Cappellen van Walsum AM, Pijnenburg YA, Berendse HW, de Munck JC, Scheltens P, van Dijk BW. Generalized synchronization of MEG recordings in Alzheimer's Disease: evidence for involvement of the gamma band. J Clin Neurophysiol. 2002 Dec;19(6):562-74. doi: 10.1097/00004691-200212000-00010.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
March 31, 2026
Study Registration Dates
First Submitted
September 17, 2020
First Submitted That Met QC Criteria
September 22, 2020
First Posted (Actual)
September 28, 2020
Study Record Updates
Last Update Posted (Actual)
September 25, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 192022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)Active, not recruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Neurofeedback
-
Kowloon Hospital, Hong KongChinese University of Hong KongCompletedStroke | Cognitive ImpairmentHong Kong
-
Insel Gruppe AG, University Hospital BernUniversity of BernRecruiting
-
University of Rhode IslandRecruitingNeurofeedbackUnited States
-
University of OxfordWellcome TrustTerminated
-
Leiden University Medical CenterCompletedElevated EEG Theta/Beta Ratio
-
National Cheng-Kung University HospitalMinistry of Science and Technology, TaiwanEnrolling by invitationHIV Infections | Poor Quality SleepTaiwan
-
University of PittsburghRecruiting
-
Laureate Institute for Brain Research, Inc.CompletedDepression | AnxietyUnited States
-
Laureate Institute for Brain Research, Inc.National Institute of General Medical Sciences (NIGMS)RecruitingDepressive Disorder, MajorUnited States
-
ETH ZurichSwiss Epilepsy Centre - Klinik LenggRecruitingHealth, Subjective | Epilepsy, Temporal Lobe | Psychogenic SeizureSwitzerland